Se desaconseja su uso en caso de insuficiencia renal o heptica
GIP, glucose-dependent insulinotropic polypeptide, improves insulin sensitivity and plays a direct role in lipid metabolism
It is being developed primarily as a treatment for obesity and type 2 diabetes, but its potential applications extend to several weight-related conditions including non-alcoholic fatty liver disease (NAFLD), knee osteoarthritis, and obstructive sleep apnoea
Compared with groups A1, 2 and 3, pH and PO 2 levels were decreased in groups B, C and D, and the difference was statistically significant
However, since oral GLP-1s regulate blood sugar levels, this can effectively improve insulin sensitivity